Acadia outlines $700M DAYBUE 2028 target as DAYBUE guidance rises to $505M-$520M (NASDAQ:ACAD)
Acadia Pharmaceuticals (ACAD) reported Q3 2026 revenues of $342M, with DAYBUE and NUPLAZID sales at $140M and $202M respectively. The company raised DAYBUE 2026 guidance to $505M-$520M and set a $700M 2028 target. CEO Catherine Owen Adams highlighted strong quarterly performance.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance provide fresh, material information that can influence trading decisions.
Market read
First‑report earnings with higher guidance for a mid‑cap biotech; likely to move the stock in the short term.
What to watch
Potential regulatory or clinical trial risks for DAYBUE that are not disclosed in the call.
Background
Acadia Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company focused on central nervous system disorders.
Ticker impact
Acadia Pharmaceuticals reported Q3 revenue of $342M, DAYBUE net sales $140M and raised DAYBUE 2028 guidance to $505M-$520M.
upside pressure as investors price in higher future sales
Guidance lift and record DAYBUE sales are fresh, material data that can move the share price in the near term.
Market effects
Positive earnings may boost sentiment in the biotech sector, especially companies with similar CNS pipelines.
U.S. biotech investors may see a modest rally, with limited spillover to broader markets.
Limited to investors tracking U.S. biotech earnings; no global macro effect.
Counterpoint
If the guidance increase is already priced in, the stock could face a short‑term pullback on profit‑taking.
Key entities
- ExecutiveCatherine Owen Adams
CEO & Director of Acadia Pharmaceuticals, provided the earnings commentary.
